Navigation Links
Agarose, Fine Resolution

ProductsAgarose, Fine Resolution
Company USB Corporation
Item Agarose, Fine Resolution
Features 
Description Ultrapure
MB Grade
PRODUCT SPECIFICATIONS
Form: Granular, free-flowing powder
EEO (-mr): less than or equal to 0.05
Gel Point (3%): less than or equal to 35C
Remelt Point (3%): less than or equal to 75C
Gel Strength (3%): greater than or equal to 300 gm/cm2
Moisture: less than or equal to 10%
Sulfate: less than or equal to 0.10%
DNase: Passes test
RNase: Passes test

CAS # 9012-36-6
Info USB Corporation
Customer Service: (800) 321-9322
Web site: http://www.usbweb.com

Related medicine products :

1. Agarose, Type C
2. Agarose, separation > 500 bp, Genetic Performance Certified †
3. Agarose, high gel strength
4. Agarose,separation < 500 bp
5. Agarose, 100g
6. Agarose, 500g
7. Agarose, high gel strength, Molecular Biology Grade
8. Agarose, high resolution, Molecular Biology Grade
9. Agarose, ultra high resolution, Molecular Biology Grade
10. Agarose, Molecular Biology Grade
11. Agarose, high purity, Molecular Biology Grade
Clearview C. Diff A is a one-step test for the direct qualitative detection of Clostridium difficile toxin A from fecal samples.
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults.
...is one of the easiest tests to run on the market t...th no hands-on time. Critical care instructions ca...g the pediatrician's office and valuable informati...help control the spread of RSV infections. Now the...
The BinaxNOW Influenza A & B Test simplifies rapid influenza testing. The easiest flu test on the market just got easier with accurate differentiation between influenza A and influenza B using one si
Medicine Products:
(Date:5/16/2008)... Minn., May 16 /PRNewswire-USNewswire/ -- This rel...yo Clinic in conjunction with the,National Cancer ...y being presented at the American Society of Clini...may change treatment practice,in about 25 percent ...,proposed changes to the way colorectal cancers wi...
(Date:5/16/2008)...being presented at the American Society of Clinica...y change treatment practice in about 25 percent of...roposed changes to the way colorectal cancers will...ancer Institute (NCI) SEER population-based statis...inical trial data, shows that outcomes of patients...
(Date:5/16/2008)... Declaring that Primary care medicine is in a pre...nt of the American College of Physicians (ACP), to...ers and consumers to issue a call for comprehensiv...nternists and other primary care physicians. , ...care medicine in the U.S., Dr. Dale and other pane...
(Date:5/16/2008)...ave Vital Services for Frail Seniors and People Wi...ire-USNewswire/ -- Thousands of,homecare workers a...zenegger,s proposed cuts to hours of service, wage...ia,s most vulnerable workers and the,people they s...se vital,services for seniors and people with disa...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2
... whether an elderly patient may develop cognitive ...published in the January issue of Neuropsychology,...ols researchers, looked at 96 community-dwelling a...ld. The participants with uric acid levels in the...
...have another look at that attractive magazine thei...nt studies, teenage girls who read articles on wei...rone to resort to drastic weight reducing techniqu... or smoking more cigarettes, than those who don’t....
...developed that can help predict the risk of bacter...id pleocytosis (presence of greater// number of wh... hospitalizations and antibiotics, according to a ... is the greatest concern when evaluating and treat...
...ding complaints from the public, a notice from the...to court, from an NGO.// The yoga guru had create...e key to curing AIDS by performing yoga and using ... Anbumani Ramadoss had earlier rubbished these sta...
Other Medicine News:Health News:Drop That Glossy, Girl! 2Health News:Clinical Guidelines Help Identify Which Children at Risk of Bacterial Meningitis 2
(Date:5/15/2008)...l Results Confirm Efficacy for Population Most Aff...alif., May 16 /-,Bayer Heal...als, Inc.,(Nasdaq: ONXX ) today announced that Ne...d overall survival by 47.3 percent (HR=0.68;,p-val...ith advanced,hepatocellular carcinoma (HCC), or pr...
(Date:5/15/2008)...ty and Efficacy Clinical Data from Prostate, Color...ncers -, - Company to Hold Investor Event on Sun....ISCO, Calif., May 15 /- Pon...pharmaceutical company focused,on oncology, today ...three,clinical trials of picoplatin, in various tu...
(Date:5/15/2008)...ressure reductions demonstrated in Blacks, Hispani...and Obese Individuals, PARSIPPANY, N.J., May 15 /...ay that data presented at the American Society of,...ting (ASH 2008) in New,Orleans demonstrated that t...and olmesartan medoxomil) safely and effectively h...
(Date:5/15/2008)...TON, May 15 /- CenterWatch, a publish...rket research about clinical,trials, finds that in...DC,(electronic data capture) systems. More than 75...dicated that they had been trained on three or mor...hat the effectiveness of,their EDC training had im...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Multiple resource management is focus of new technical report 2436 1D1 Spas Unveils Worlds First Underwater Gym at IHRSA 2008 13773 1D1 Spas Unveils Worlds First Underwater Gym at IHRSA 2008 13773 2D1 Spas Unveils Worlds First Underwater Gym at IHRSA 2008 13773 3D1 Spas Unveils Worlds First Underwater Gym at IHRSA 2008 13773 4Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane Tesetaxel 13769 1Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane Tesetaxel 13769 2Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane Tesetaxel 13769 3Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane Tesetaxel 13769 4Rett syndrome research reveals high fracture risk 13765 1
...)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ...mpany, presented first-time data from a pre-clinic...ect of nab-rapamycin,(ABI-009), an albumin-bound m...tion for Cancer Research (AACR) Annual Meeting hel...he pre-clinical,study demonstrated that nab-rapamy...
..., 2007 /PRNewswire-FirstCall/ --,Idenix Pharmaceut...in the discovery, development and commercializatio...her infectious diseases,announced today that 11 a...e 2007 Digestive Disease Week (DDW) meeting, to,be...stract contents,are available on the DDW web site ...
Other Medicine Technology:Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 2Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 3Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 4Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 5Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 6Idenix Announces Data Presentations at the 2007 Digestive Disease,Week Meeting 7